These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 34779569)

  • 41. Thromboembolic Risk of 4-Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department.
    Maguire M; Fuh L; Goldstein JN; Marshall AL; Levine M; Howell ML; Parry BA; Rosovsky R; Hayes BD
    West J Emerg Med; 2019 Jul; 20(4):619-625. PubMed ID: 31316701
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents.
    Siegal DM
    J Thromb Thrombolysis; 2015 Apr; 39(3):395-402. PubMed ID: 25586208
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
    Sin JH; Berger K; Lesch CA
    J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect.
    Nagakari K; Emmi M; Iba T
    Clin Appl Thromb Hemost; 2017 Sep; 23(6):677-684. PubMed ID: 26984934
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Management of urgent invasive procedures in patients treated with direct oral anticoagulants: An observational registry analysis.
    Godon A; Gabin M; Levy JH; Huet O; Chapalain X; David JS; Tacquard C; Sattler L; Minville V; Mémier V; Blanié A; Godet T; Leone M; De Maistre E; Gruel Y; Roullet S; Vermorel C; Samama CM; Bosson JL; Albaladejo P;
    Thromb Res; 2022 Aug; 216():106-112. PubMed ID: 35785621
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
    Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ;
    Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical Relevance of Preclinical and Clinical Studies of Four-Factor Prothrombin Complex Concentrate for Treatment of Bleeding Related to Direct Oral Anticoagulants.
    Sarode R; Welsby IJ; Hoffman M
    Ann Emerg Med; 2023 Sep; 82(3):341-361. PubMed ID: 37204347
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.
    Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ
    J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage.
    Oh ES; Schulze P; Diaz F; Shah K; Rios J; Silverman ME
    Am J Emerg Med; 2023 Feb; 64():74-77. PubMed ID: 36463661
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Management of hemorrhage in patients treated with direct oral anticoagulants].
    Grottke O; Lier H; Hofer S
    Anaesthesist; 2017 Sep; 66(9):679-689. PubMed ID: 28455651
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reversal strategies in patients treated with direct oral anticoagulants.
    Gressenberger P
    Vasa; 2019 Aug; 48(5):389-392. PubMed ID: 30719950
    [No Abstract]   [Full Text] [Related]  

  • 52. Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding.
    Stevens VM; Trujillo TC; Kiser TH; MacLaren R; Reynolds PM; Mueller SW
    Clin Appl Thromb Hemost; 2021; 27():10760296211039020. PubMed ID: 34541920
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factor VIII Inhibitor Bypassing Activity (FEIBA) Reversal for Apixaban and Rivaroxaban in Patients With Acute Intracranial and Nonintracranial Hemorrhage.
    Hunt AR; Coffeen SN; Shiltz DL; Ice C; Parker J
    Ann Pharmacother; 2021 Dec; 55(12):1455-1466. PubMed ID: 33843267
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor-associated bleeding: Case series.
    Liu J; Elsamadisi P; Philips E; Bauer KA; Eche IM
    Am J Health Syst Pharm; 2022 Aug; 79(16):1323-1329. PubMed ID: 35291008
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hemostatic Efficacy and Safety of 4-Factor Prothrombin Complex Concentrate in Doac-Associated Intracranial Hemorrhage.
    Whaley PM; Franco-Martinez C; Lock AE; Ramaswamy D; Young EH; Allen SM; Barthol CA
    J Pharm Pract; 2024 Jun; 37(3):557-562. PubMed ID: 36564900
    [No Abstract]   [Full Text] [Related]  

  • 56. Safety and effectiveness of a prothrombin complex concentrate in approved and off-label indications.
    Marcos-Jubilar M; García Erce JA; Martínez-Calle N; Páramo JA; Martínez Virto A; Quintana-Díaz M
    Transfus Med; 2019 Aug; 29(4):268-274. PubMed ID: 31347218
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of Direct Oral Anticoagulant Reversal Agents in Intracranial Hemorrhage: A Systematic Review and Meta-analysis.
    Chaudhary R; Singh A; Chaudhary R; Bashline M; Houghton DE; Rabinstein A; Adamski J; Arndt R; Ou NN; Rudis MI; Brown CS; Wieruszewski ED; Wanek M; Brinkman NJ; Linderbaum JA; Sorenson MA; Atkinson JL; Thompson KM; Aiyer AN; McBane RD
    JAMA Netw Open; 2022 Nov; 5(11):e2240145. PubMed ID: 36331504
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Four-Factor Prothrombin Complex Concentrate for the Reversal of Direct Oral Anticoagulants.
    Zada I; Wang S; Akerman M; Hanna A
    J Intensive Care Med; 2021 Jan; 36(1):58-62. PubMed ID: 31746285
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Newer clinically available antithrombotics and their antidotes.
    Lévy S
    J Interv Card Electrophysiol; 2014 Sep; 40(3):269-75. PubMed ID: 24934756
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates.
    Panos NG; Cook AM; John S; Jones GM;
    Circulation; 2020 May; 141(21):1681-1689. PubMed ID: 32264698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.